Settings Today

iTeos Therapeutics (NASDAQ:ITOS) Receives “Outperform” Rating from Wedbush

iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer and autoimmune diseases. The company's lead product candidate is ITOS-101, an oral small molecule targeting the PI3K/AKT pathway in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

On February 24, 2022, Wedbush Securities initiated coverage on iTeos Therapeutics with an "Outperform" rating and a price target of $15.00 per share. The analysts at Wedbush cited the company's strong clinical data for ITOS-101 in DLBCL patients, as well as its potential to expand into other indications such as non-Hodgkin's lymphoma and multiple myeloma.

iTeos Therapeutics has also recently announced plans to initiate a phase 2 clinical trial of ITOS-101 in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients who have failed prior therapies, including CAR-T cell therapy. The company expects to report top-line data from this trial in the second half of 2022.

Overall, Wedbush's "Outperform" rating reflects the analysts' confidence in iTeos Therapeutics' ability to successfully develop and commercialize ITOS-101, as well as its potential for future growth and expansion into new indications.


Published 292 days ago

Go Back to Reading NewsBack Read News Collect this News Article


For peering opportunity Autonomouse System Number: AS401345 Custom Software Development at ErnesTech Email Address[email protected]